Jazz Pharmaceuticals, Inc. (JAZZ) is a publicly traded Healthcare sector company. As of May 21, 2026, JAZZ trades at $237.51 with a market cap of $14.40B and a P/E ratio of 26.45. JAZZ moved +0.70% today. Year to date, JAZZ is +37.05%; over the trailing twelve months it is +115.29%. Its 52-week range spans $95.49 to $242.18. Analyst consensus is strong buy with an average price target of $241.43. Rallies surfaces JAZZ's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies AI research for JAZZ combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.
| Metric | Value |
|---|---|
| Price | $237.51 |
| Market Cap | $14.40B |
| P/E Ratio | 26.45 |
| EPS | $9.06 |
| Dividend Yield | 0.00% |
| 52-Week High | $242.18 |
| 52-Week Low | $95.49 |
| Volume | 36 |
| Avg Volume | 0 |
| Revenue (TTM) | $4.07B |
| Net Income | $560.12M |
| Gross Margin | 0.00% |
15 analysts cover JAZZ: 0 strong buy, 14 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $241.43.